In accordance with the provisions of Court Rule 4:38A and Directive #02-19, “Multicounty Litigation Guidelines and Criteria for Designation (Revised)," a previous Notice to the Bar sought comments on the recommendation of Superior Court Judge John C. Porto for conclusion of the Accutane litigation centralized management and handling as MCL. This Notice is to advise that the Supreme Court, after considering the recommendation and having received no comments objecting to the conclusion, has concluded the MCL designation and centralized management of all pending and future state-court litigation involving use of the drug Accutane.
Published with this Notice is the Court's May 6, 2022 Order, which is posted with this Notice on the Judiciary's Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center http://www.njcourts.gov/attorneys/mcl/index.html.
Questions concerning the Court's conclusion of the MCL designation of the Accutane Litigation may be directed to Melissa A. Czartoryski, Esq., Chief, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov
SUPREME COURT OF NEW JERSEY
The Supreme Court by Order dated May 2, 2005 designated all New Jersey state court litigation relating to Accutane for centralized management as a mass tort (now multicounty litigation) and assigned that litigation to Atlantic County. The Court's initial Order has since been amended as to the designated judge, including most recently by Order dated April 15, 2019.
It is ORDERED that effective immediately, the designation of all New Jersey state court Accutane litigation for centralized management and treatment as multicounty litigation is hereby concluded.
Document Date: May 11, 2022
Publish Date: May 12, 2022